

DSU Report for NICE – Azacitidine STA Economic Model 09/12/09

The DSU were asked to re-examine the above economic model, following the request for clarifications and amendments to the model.

I have examined both the written response from Celgene and the revised economic model (both of which contained in Jeremy Powell's email on 27/11/09).

All the corrections that the DSU requested have been fully and satisfactorily addressed.

Specifically, the company have:

1. Ensured that the deterministic and PSA results contained in the model match those in the corresponding report.
2. Fixed the problems with the transition probabilities in so much that they now 'look back' rather than 'look forward'. The DSU can therefore confirm that the various transition probabilities (e.g. for the Gompertz and Weibull curves) are being calculated properly given the related parameters. While the DSU was not asked to comment on whether the appropriate survival curves, were, in the first instance, being used, it is noted that overall patient survival curves are being used in the model to estimate not only the time to death, but also the transition from the MDS to ADL health state. The DSU feel this is an assumption that the Committee should be aware of, if not already the case.
3. Ensured the PSA now runs properly.
4. Ensured the correct distributional parameters relate to the correct patient sub-groups.

Alec Miners, on behalf of the DSU